←Back to Expert Scholars
Translational Medicine / 转化医学HER2 Ultra-Low
Sara Tolaney
MD, MPH
🏢Dana-Farber Cancer Institute🌐USA
Chief, Division of Breast Oncology
68
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Sara Tolaney is chief of breast oncology at Dana-Farber and leader in HER2 therapy development. She contributes to DESTINY trials and studies of HER2-ultralow biology in early disease. Her work is reshaping HER2 classification across the ultra-low spectrum.
Share:
🧪Research Fields 研究领域
HER2 ADCs
Adjuvant trials
Early breast cancer
Translational biomarkers
CDK4/6 combinations
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Sara Tolaney 的研究动态
Follow Sara Tolaney's research updates
留下邮箱，当我们发布与 Sara Tolaney（Dana-Farber Cancer Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment